IRON DEXTRAN Drug Patent Profile
✉ Email this page to a colleague
When do Iron Dextran patents expire, and when can generic versions of Iron Dextran launch?
Iron Dextran is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in IRON DEXTRAN is ferric oxyhydroxide. There are twenty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the ferric oxyhydroxide profile page.
Summary for IRON DEXTRAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 34 |
Clinical Trials: | 64 |
Patent Applications: | 897 |
What excipients (inactive ingredients) are in IRON DEXTRAN? | IRON DEXTRAN excipients list |
DailyMed Link: | IRON DEXTRAN at DailyMed |
Recent Clinical Trials for IRON DEXTRAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Menoufia University | Phase 4 |
Tanta University | Phase 4 |
Women and Infants Hospital of Rhode Island | Phase 3 |
US Patents and Regulatory Information for IRON DEXTRAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | IRON DEXTRAN | ferric oxyhydroxide | INJECTABLE;INJECTION | 010787-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |